SELLAS Life Sciences announced on November 17, 2026, that its phase 3 REGAL trial of galinpepimut-S (GPS), a Wilms tumor 1 (WT1)-targeted immunotherapeutic cancer vaccine, met its primary end point of overall survival (OS) in patients with acute myeloid leukemia (AML).¹ GPS reduced the risk of death by 41% compared with investigator's choice of best available treatment (BAT). Median OS was 24.0 months with GPS vs 14.7 months with BAT (hazard ratio, 0.59; 2-sided p=.035).¹
Key facts
- Drug: galinpepimut-S (GPS; SELLAS Life Sciences)
- Class: WT1-targeted peptide immunotherapeutic cancer vaccine
- Indication studied: AML maintenance in CR2/CRp2 or later, transplant ineligible
- Trial: REGAL (NCT04229979); phase 3, randomized, open-label, n=126
- Primary end point met: Median OS 24.0 vs 14.7 months (HR, 0.59; p=.035)
- Comparator: Investigator's choice of best available treatment
- Safety: Mostly grade 1 or 2; injection site reactions most common
- Regulatory status: FDA meeting planned; BLA targeted for first half of 2027
- Origin: Licensed from Memorial Sloan Kettering Cancer Center
- Next data: Secondary end points at an upcoming medical conference
“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission,” said Angelos Stergiou, MD, ScD h.c., president and CEO, SELLAS, in a company press release.¹
What did the REGAL trial evaluate?
REGAL (NCT04229979) is a global, randomized, open-label trial testing GPS as maintenance monotherapy in patients with AML. Eligible patients had reached a second or later complete remission (CR2 or later), or complete remission with insufficient platelet recovery (CRp2 or later), after second- or later-line salvage therapy. They also had to be ineligible for, or unable to undergo, allogeneic stem cell transplantation.¹,² A total of 126 patients were randomized 1:1 to GPS or BAT, which included observation, a hypomethylating agent, venetoclax, and/or low-dose cytarabine.¹
The topline analysis was run after the prespecified 80 deaths, as set out in the trial's statistical analysis plan.¹ The treatment arms were balanced for prognostic stratification factors. Few patients went on to hematopoietic stem cell transplantation, and they were evenly split between the arms.¹
What was the safety profile?
GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals.¹ Treatment-related adverse events were mostly grade 1 or 2, most commonly local injection site reactions.¹
How does GPS work?
GPS is an investigational off-the-shelf vaccine licensed from Memorial Sloan Kettering Cancer Center. It consists of 4 WT1-derived peptides designed to stimulate CD4+ and CD8+ T-cell responses across multiple human leukocyte antigen types.¹ WT1 is expressed in a broad range of hematologic malignancies and solid tumors, including AML, and GPS is intended to direct the immune system against residual WT1-expressing cancer cells.¹ In an earlier phase 2 trial of 22 patients with AML, 9 of 14 tested patients (64%) had a CD4 or CD8 immune response. The most common toxicities were grade 1 or 2 injection site reactions (46%).³